• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

19.95 +0.06 (+0.30%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,573,099
Open 20.01
Bid (Size) 19.85 (200)
Ask (Size) 20.47 (500)
Prev. Close 19.89
Today's Range 19.88 - 20.24
52wk Range 19.59 - 30.96
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
September 29, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
September 28, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire

Performance

52-Week Range 35.6% below 52-week high
19.95
19.5952W Low 30.9652W High
1 Week 3.6% below 1-week high
19.591W Low 20.701W High

ACADIA Pharmaceuticals Inc. - Common Stock (ACAD) traded between $19.59 and $30.96 over the past 52 weeks and last traded at $19.95, 35.6% below its 52-week high. Over the past week it ranged between $19.59 and $20.70.

Past 12 Months
-2.8%
-31.0%
-22.6%
-10.6%
-24.1%
-6.7%
1W -$0.58
1M -$8.98
3M -$5.82
6M -$2.37
YTD -$6.34
1Y -$1.43

ACAD was -6.7% over the past year, -10.6% over six months, -24.1% year to date, -2.8% in the last week.

12 Months vs Market
ACAD
-6.7%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months ACAD returned -6.7% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 1.42× 3-mo avg
Today 2,573,099 3-mo avg 1.8M
1W
2.9M
1M
2.3M
3M
1.8M
6M
1.8M
YTD
1.7M
1Y
1.7M

ACAD most recently traded 2,573,099 shares against a 3-month average daily volume of 1.8M.

More News

Read More
News headline image
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial ↗
September 24, 2026
Via MarketBeat
News headline image
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
September 24, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA Pharmaceuticals (NASDAQ:ACAD) Displays High Growth Momentum and a Breakout Setup ↗
August 31, 2026
Via Chartmill
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 Earnings Beat, Stock Rises on Raised Guidance ↗
August 04, 2026
Via Chartmill
Topics Earnings
News headline image
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
August 24, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data ↗
August 12, 2026
Via MarketBeat
News headline image
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript ↗
August 11, 2026
Via The Motley Fool
Topics Earnings
Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower ↗
May 06, 2026
Via Chartmill
Topics Earnings
News headline image
ACADIA Pharmaceuticals Q2 Earnings Call Highlights ↗
August 04, 2026
Via MarketBeat
Topics Earnings
News headline image
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 04, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 30, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
July 20, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
July 15, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors? ↗
July 11, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
July 06, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Why Acadia Pharmaceuticals Stock Is Soaring Today ↗
June 26, 2026
Via The Motley Fool
Traders are paying attention to the gapping stocks in Friday's session. ↗
June 26, 2026
Via Chartmill
News headline image
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday ↗
June 26, 2026
Via Benzinga
News headline image
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
June 26, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth ↗
May 19, 2026
Via MarketBeat
News headline image
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms ↗
May 12, 2026
Via MarketBeat
News headline image
Acadia (ACAD) Q1 2026 Earnings Transcript ↗
May 06, 2026
Via The Motley Fool
News headline image
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
May 06, 2026
From Acadia Pharmaceuticals Inc.
Via Business Wire

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 19.95
When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.24B
How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
ACADIA Pharmaceuticals Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap